Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMW4CR8)

Drug Name
Iscalimab Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMW4CR8

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40L receptor (CD40) TTN6Y9A TNR5_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
CD40L receptor (CD40) DTT CD40 4.629 4.991 5.53 3.385
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type-1 diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD40L receptor (CD40) DTT CD40 4.61E-01 0.56 0.5
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04129528) Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM). U.S.National Institutes of Health.
2 Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.